The FDA has now approved two oral agents for paroxysmal nocturnal hemoglobinuria, a rare and life-threatening blood disorder that destroys red blood cells and leaves patients dependent on costly intravenous infusions. Fabhalta (iptacopan), manufactured by Novartis, received approval on December 6, 2023, as the first oral monotherapy for PNH in adults, while Voydeya (danicopan), from Alexion/AstraZeneca, followed on March 29, 2024, as the first oral add-on therapy. For patients and caregivers already managing complex treatment regimens — particularly those also navigating neurodegenerative conditions — these approvals represent a meaningful shift away from the infusion chair and toward pharmacy-dispensed pills taken at home. These developments matter beyond hematology.
PNH can cause fatigue, cognitive fog, and quality-of-life impairments that overlap with or worsen symptoms in people living with dementia and other neurological conditions. Chronic hemolysis starves tissues of oxygen, and the brain is especially vulnerable to that deficit. For families coordinating care across multiple specialists, the availability of oral treatment options could simplify logistics and reduce the burden of hospital visits. This article examines what these new drugs do, how they performed in clinical trials, what they cost, and what patients and caregivers should realistically expect as the PNH treatment landscape continues to evolve.
Table of Contents
- What Are the New Oral Agents Approved for Paroxysmal Nocturnal Hemoglobinuria?
- How Effective Are Fabhalta and Voydeya Based on Clinical Trial Data?
- Why Oral PNH Treatment Matters for Brain Health and Dementia Caregiving
- Comparing Fabhalta and Voydeya — Which Oral PNH Treatment Fits Which Patient?
- Side Effects, Safety Concerns, and What Patients Should Watch For
- Understanding the Cost of New PNH Oral Therapies
- The Future of PNH Treatment and What It Signals for Rare Disease Care
- Conclusion
- Frequently Asked Questions
What Are the New Oral Agents Approved for Paroxysmal Nocturnal Hemoglobinuria?
Paroxysmal nocturnal hemoglobinuria occurs when a genetic mutation causes red blood cells to lack protective surface proteins, making them targets for the body’s own complement system. Until recently, the only FDA-approved treatments were intravenous complement inhibitors — eculizumab (Soliris) and ravulizumab (Ultomiris) — which block the C5 protein. These drugs changed survival outcomes dramatically but required regular infusion appointments, sometimes every two weeks, and came with annual price tags exceeding $400,000. Fabhalta and Voydeya attack the complement cascade at different points upstream, and critically, both are taken by mouth. Fabhalta is a first-in-class oral complement Factor B inhibitor that targets the alternative complement pathway.
Patients take 200 mg twice daily. It works as a standalone treatment, meaning eligible patients can potentially stop their intravenous infusions entirely. Voydeya, by contrast, is a first-in-class oral complement Factor D inhibitor designed to be taken alongside existing anti-C5 therapy — ravulizumab or eculizumab — rather than replacing it. Its standard dose is 150 mg three times daily, with the option to increase to 200 mg three times daily based on clinical response. The distinction matters: Fabhalta replaces the infusion, while Voydeya supplements it. For a patient who is partially responding to infusion therapy but still experiencing hemolysis, Voydeya adds a layer of protection without requiring a full treatment switch.
How Effective Are Fabhalta and Voydeya Based on Clinical Trial Data?
The clinical evidence behind both drugs is strong, though their trial designs reflect their different roles. Fabhalta’s APPLY-PNH trial enrolled patients who were already on anti-C5 therapy and switched them to oral iptacopan. The results were striking: 82.3% of patients on Fabhalta achieved hemoglobin increases of 2 g/dL or more, compared to 0% of those who continued their anti-C5 infusions. Even more telling, 67.7% of Fabhalta patients reached hemoglobin levels of 12 g/dL or above — a threshold considered normal — versus none in the comparator group. Transfusion avoidance hit 95.2% on Fabhalta compared to 45.7% on continued anti-C5 therapy, a difference that was statistically significant at p <0.0001. A separate trial, APPOINT-PNH, looked at treatment-naive patients and found 92.2% achieved both transfusion independence and hemoglobin improvement of at least 2 g/dL at 24 weeks. Voydeya's ALPHA Phase 3 trial took a different approach, since the drug is meant as add-on therapy.
In a double-blind, placebo-controlled study, 49 patients received danicopan on top of their existing anti-C5 regimen, while 24 received placebo plus anti-C5 therapy. At 12 weeks, hemoglobin improved by 2.94 g/dL in the danicopan group versus just 0.50 g/dL in the placebo group. The trial met its primary endpoint and key secondary endpoints, including improvements in transfusion avoidance and FACIT-Fatigue scores — a validated measure of how tired patients feel in daily life. Long-term follow-up showed these clinical improvements held through 72 weeks, with no new safety concerns. However, these trials enrolled relatively small populations, which is characteristic of rare disease research but limits the ability to detect uncommon adverse events. If a side effect occurs in 1 out of 500 patients, a 49-person trial will almost certainly miss it. Post-marketing surveillance will be essential, and patients starting either drug should discuss the reality of limited long-term safety data with their hematologist.
Why Oral PNH Treatment Matters for Brain Health and Dementia Caregiving
The connection between a rare blood disorder and brain health may not be immediately obvious, but chronic hemolysis — the hallmark of PNH — has downstream effects that directly impact the central nervous system. When red blood cells break apart, hemoglobin levels drop and free hemoglobin circulates in the blood, scavenging nitric oxide. The result is vasoconstriction, impaired blood flow, and reduced oxygen delivery to organs, with the brain taking a disproportionate hit. Patients with PNH frequently report cognitive difficulties, extreme fatigue, and difficulty concentrating — symptoms that can mimic or compound those of early-stage dementia.
For older adults who may be living with both PNH and a neurodegenerative condition, the practical burden of infusion therapy is substantial. A typical eculizumab regimen requires visits to an infusion center every two weeks, each lasting several hours. For someone with cognitive impairment who depends on a caregiver for transportation and supervision, that schedule can consume an outsized share of the family’s time and energy. An oral pill taken at home eliminates the travel, the waiting room, the IV access, and the recovery time afterward. Consider a 72-year-old patient with mild cognitive impairment and PNH: switching from biweekly infusions to twice-daily Fabhalta tablets could free up dozens of hours per month for the caregiver and reduce the disorientation that clinic visits often cause for cognitively vulnerable patients.
Comparing Fabhalta and Voydeya — Which Oral PNH Treatment Fits Which Patient?
The choice between Fabhalta and Voydeya is not simply a matter of preference — it depends on a patient’s clinical situation and treatment history. Fabhalta is positioned for patients who are candidates for monotherapy, particularly those who have been on anti-C5 agents and want to transition entirely to an oral regimen. The APPLY-PNH data supports this switch, showing dramatic improvements over continued infusion therapy. For treatment-naive patients, the APPOINT-PNH trial data is equally compelling, suggesting Fabhalta can serve as a first-line option without ever starting infusions. Voydeya fills a different niche.
It was developed for patients who are already on ravulizumab or eculizumab but continue to experience extravascular hemolysis — a type of red blood cell destruction that anti-C5 drugs do not fully address. Adding Voydeya to the existing regimen targets this residual hemolysis without abandoning the proven C5 blockade. The tradeoff is clear: Voydeya does not eliminate infusion visits, but it does improve hemoglobin levels and reduce fatigue in patients whose current therapy is falling short. Voydeya also carries an FDA Breakthrough Therapy designation and European Medicines Agency PRIME status, reflecting its importance for an unmet need. Patients and their care teams should weigh whether the goal is to simplify the regimen entirely (favoring Fabhalta) or to optimize an existing one (favoring Voydeya). Neither drug is universally superior — the right choice depends on the clinical context.
Side Effects, Safety Concerns, and What Patients Should Watch For
Both Fabhalta and Voydeya carry side effect profiles that patients and caregivers need to understand before starting treatment. Common adverse effects reported with Fabhalta include headache, nasopharyngitis, diarrhea, abdominal pain, bacterial and viral infections, nausea, and rash. While none of these are unusual for complement-targeting therapies, the infection risk deserves particular attention. Complement proteins are a core part of the innate immune system, and inhibiting them — whether at Factor B, Factor D, or C5 — leaves patients more susceptible to encapsulated bacterial infections, including meningococcal disease. Vaccination against Neisseria meningitidis is standard practice before initiating any complement inhibitor, and this requirement applies to the oral agents as well.
For patients with cognitive impairment, the pill burden itself introduces a safety consideration. Fabhalta’s twice-daily dosing is relatively straightforward, but Voydeya requires three doses per day with a possible increase to three higher-dose tablets daily. Missed doses can lead to breakthrough hemolysis, which in severe cases can be life-threatening. Caregivers managing medications for someone with dementia should establish a reliable pillbox and alarm system before starting either drug. If adherence cannot be reasonably assured — for instance, if a patient lives alone and has moderate-to-severe cognitive impairment — the treating physician may determine that continued infusion therapy, administered under clinical supervision, is actually the safer option despite its logistical drawbacks.
Understanding the Cost of New PNH Oral Therapies
The annual list price of Fabhalta is approximately $550,377 per year, or about $46,562 per 30-day supply, placing it squarely in the category of ultra-high-cost specialty medications. That number can induce sticker shock, but Novartis reports that 92% of prescriptions currently cost patients $0 per month, with an average out-of-pocket cost of just $22 per fill. This gap between list price and actual patient cost reflects the role of manufacturer copay assistance programs, specialty pharmacy negotiations, and insurance coverage pathways that are now standard in the rare disease space.
Still, these assistance programs are not guaranteed to last indefinitely, and patients on Medicare or Medicaid may face different cost-sharing structures. Families should work with a specialty pharmacist and their insurance provider to verify coverage before assuming the out-of-pocket figure will hold in their case. For households already stretched thin by dementia care costs — which the Alzheimer’s Association estimates at over $350,000 in lifetime out-of-pocket expenses for a typical family — adding any new specialty medication warrants a careful financial conversation with the care team and a social worker.
The Future of PNH Treatment and What It Signals for Rare Disease Care
The PNH market is entering what analysts at Spherix Global Insights described in March 2026 as a transition phase, with second-line treatment opportunities expanding even as barriers to adoption of newer agents persist. There are now four FDA-approved treatments for PNH in total, giving clinicians more flexibility than at any point in the disease’s history. The trajectory is clear: oral therapies will likely continue to gain ground over infusion-based regimens, particularly as real-world evidence accumulates and physicians grow more comfortable prescribing them as first-line options.
For the broader rare disease community, the approval of oral complement inhibitors signals that the era of exclusively hospital-administered biologics may be winding down for certain conditions. This has particular relevance for aging patients and their caregivers, who stand to benefit most from treatments that can be managed at home. As drug developers continue to pursue oral formulations for conditions that once required IV access, the intersection of hematology, neurology, and geriatric care will become an increasingly important space to watch.
Conclusion
The FDA approvals of Fabhalta and Voydeya mark a genuine turning point for adults living with paroxysmal nocturnal hemoglobinuria. For the first time, patients have oral treatment options — one that can replace infusion therapy entirely and another that can be layered on top of existing regimens to address residual hemolysis. The clinical trial data supporting both drugs is robust, with substantial improvements in hemoglobin levels, transfusion avoidance, and fatigue scores compared to previous standards of care. For families navigating PNH alongside dementia or other cognitive conditions, these oral agents offer more than pharmacological progress — they offer practical relief from the logistical weight of infusion schedules.
That said, neither drug is without limitations. Cost remains astronomical at list price, adherence requires reliable medication management, and long-term safety data is still accumulating. Patients and caregivers should have candid conversations with their hematologists about which option best fits their clinical needs, cognitive capacity for self-management, and financial situation. The tools are better than they have ever been, but using them wisely still requires careful, individualized decision-making.
Frequently Asked Questions
What is paroxysmal nocturnal hemoglobinuria?
PNH is a rare, acquired blood disorder in which the body’s complement system destroys its own red blood cells due to a genetic mutation that strips protective proteins from cell surfaces. It causes severe anemia, fatigue, blood clots, and organ damage, and affects roughly 1 to 2 people per million.
Can Fabhalta completely replace IV infusion therapy for PNH?
Yes. Fabhalta (iptacopan) is approved as a standalone oral monotherapy. In the APPLY-PNH trial, patients who switched from anti-C5 infusions to Fabhalta saw significantly better hemoglobin levels and transfusion avoidance than those who stayed on infusions. However, the switch should be managed by a hematologist experienced in PNH care.
Is Voydeya taken instead of infusions?
No. Voydeya (danicopan) is specifically approved as an add-on to existing ravulizumab or eculizumab infusion therapy. It targets extravascular hemolysis that anti-C5 drugs do not fully control. Patients on Voydeya continue their infusion schedule.
Are these oral PNH drugs safe for elderly patients with cognitive impairment?
Both drugs have manageable side effect profiles, but adherence is a concern for patients with cognitive difficulties. Fabhalta requires two pills daily; Voydeya requires three. Missed doses can trigger dangerous breakthrough hemolysis. Caregivers should establish structured medication management before starting treatment, and in some cases, supervised infusion therapy may remain the safer choice.
How much do these oral PNH treatments cost out of pocket?
Fabhalta’s list price is roughly $550,377 per year, but Novartis reports that 92% of prescriptions cost patients $0 per month through assistance programs, with an average copay of $22 per fill. Actual costs vary by insurance plan, and Medicare or Medicaid patients may face different cost-sharing arrangements.
How many FDA-approved treatments for PNH exist now?
As of 2026, there are four FDA-approved treatments for PNH: eculizumab (Soliris), ravulizumab (Ultomiris), iptacopan (Fabhalta), and danicopan (Voydeya). The first two are intravenous, and the latter two are oral.
